Why Chemists Can’t Quit Palladium
“Every pharmaceutical we produce at some point or another has a palladium-catalysed step in it,” says Per-Ola Norrby, a pharmaceutical researcher at drug giant AstraZeneca in Gothenburg, Sweden. Palladium-catalysed reactions are so valuable that, in 2010, their discoverers shared a Nobel prize. But despite its versatility, chemists are trying to move away from palladium. The metal is more expensive than gold, and molecules that contain palladium can also be extremely toxic to humans and wildlife. Chemical manufacturers have to separate out all traces of palladium from their products and carefully dispose of the hazardous waste, which adds extra expense. Thomas Fuchb, a medicinal chemist at the life-sciences company Merck in Darmstadt, Germany, gives the example of a reaction to make 3 kilograms of a drug molecule for which the ingredients cost US$250,000. The palladium catalyst alone adds $100,000; purifying it out of the product another $30,000.
Finding less-toxic alternatives to the metal could help to reduce environmental harm from palladium waste and move the chemicals industry towards ‘greener’ reactions, says Tianning Diao, an organometallic chemist at New York University. Researchers hope to swap palladium for more common metals, such as iron and nickel, or invent metal-free catalysts that sidestep the issue altogether. Several times in the past two decades, researchers have reported finding palladium-free catalysts. But in what has become a recurring pattern for the field, each heralded discovery turned out to be a mistake.
Read more of this story at Slashdot.